-
公开(公告)号：US20050238649A1
公开(公告)日：2005-10-27
申请号：US10983340
申请日：2004-11-05
申请人： Svetlana Doronina , Peter Senter , Brian Toki , Allen Ebens , Toni Kline , Paul Polakis , Mark Sliwkowski , Susan Spencer
发明人： Svetlana Doronina , Peter Senter , Brian Toki , Allen Ebens , Toni Kline , Paul Polakis , Mark Sliwkowski , Susan Spencer
IPC分类号： A61K38/00 , A61K38/06 , A61K39/395 , A61K47/48 , C07K16/46
CPC分类号： C07K16/32 , A61K38/00 , A61K47/6811 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K2039/505 , C07K7/02 , C07K2317/24 , Y02A50/414 , Y02A50/423 , Y02A50/469 , Y02A50/491 , Y02A50/492 , Y10T428/13
摘要： Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
摘要翻译： 制备包括MeVal-Val-Dil-Dap-Norephedrine（MMAE）和MeVal-Val-Dil-Dap-Phe（MMAF）的Auristatin肽，并通过各种接头包括马来酰亚胺酰基val-cit-PAB连接到配体上。 所得配体药物偶联物在体外和体内都是活性的。
-
公开(公告)号：US20050276812A1
公开(公告)日：2005-12-15
申请号：US11141344
申请日：2005-05-31
申请人： Allen Ebens , Frederic Jacobson , Paul Polakis , Ralph Schwall , Mark Sliwkowski , Susan Spencer
发明人： Allen Ebens , Frederic Jacobson , Paul Polakis , Ralph Schwall , Mark Sliwkowski , Susan Spencer
IPC分类号： A61K39/395 , A61K47/48 , A61P35/00 , C07D491/14 , C07D498/18 , C07K16/10 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/46 , G01N33/574
CPC分类号： A61K47/6803 , A61K47/6875 , A61K2039/505 , C07D498/18 , C07K16/1063 , C07K16/28 , C07K16/2803 , C07K16/283 , C07K16/2866 , C07K16/2896 , C07K16/3046 , C07K16/3069 , C07K16/32 , C07K2317/24
摘要： The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.
摘要翻译： 本发明涉及式I的抗体 - 药物偶联化合物：<？in-line-formula description =“In-line Formulas”end =“lead”？> Ab-（LD） 其中一个或多个美登木素生物碱药物部分（D）通过L共价连接到与ErbB受体结合的抗体（Ab）上，其中<？in-line-formula description =“In-line Formulas”end =“tail” 或其结合一种或多种肿瘤相关抗原或细胞表面受体。 这些化合物可用于诊断或治疗癌症及其它疾病和病症的方法中。
-
公开(公告)号：US20080124331A1
公开(公告)日：2008-05-29
申请号：US11733861
申请日：2007-04-11
申请人： Belinda Cairns , Ruihuan Chen , Gretchen Frantz , Kenneth Hillan , Hartmut Koeppen , Heidi Phillips , Paul Polakis , Susan Spencer , Victoria Smith , P. Williams , Thomas Wu , Zemin Zhang , Mark Sliwkowski
发明人： Belinda Cairns , Ruihuan Chen , Gretchen Frantz , Kenneth Hillan , Hartmut Koeppen , Heidi Phillips , Paul Polakis , Susan Spencer , Victoria Smith , P. Williams , Thomas Wu , Zemin Zhang , Mark Sliwkowski
IPC分类号： A61K31/70 , A61K39/395 , A61P43/00 , C07H21/04 , C07K16/18 , C12N5/06 , G01N33/574
CPC分类号： G01N33/57484 , A61K47/60 , A61K47/6803 , A61K47/6809 , A61K47/6817 , A61K47/6839 , A61K47/6851 , A61K47/6859 , A61K51/1006 , A61K51/1018 , A61K2039/505 , C07K16/1072 , C07K16/18 , C07K16/30 , C07K16/303 , C07K2317/73 , C07K2317/76 , C07K2317/77
摘要： The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
-
公开(公告)号：US20050106644A1
公开(公告)日：2005-05-19
申请号：US10936626
申请日：2004-09-08
申请人： Belinda Cairns , Ruihuan Chen , Gretchen Frantz , Kenneth Hillan , Hartmut Koeppen , Heidi Phillips , Paul Polakis , Susan Spencer , Victoria Smith , P. Williams , Thomas Wu , Zemin Zhang , Mark Sliwkowski
发明人： Belinda Cairns , Ruihuan Chen , Gretchen Frantz , Kenneth Hillan , Hartmut Koeppen , Heidi Phillips , Paul Polakis , Susan Spencer , Victoria Smith , P. Williams , Thomas Wu , Zemin Zhang , Mark Sliwkowski
IPC分类号： C07K16/18 , C07K16/30 , C07H21/04 , G01N33/574
CPC分类号： G01N33/57484 , A61K47/60 , A61K47/6803 , A61K47/6809 , A61K47/6817 , A61K47/6839 , A61K47/6851 , A61K47/6859 , A61K51/1006 , A61K51/1018 , A61K2039/505 , C07K16/1072 , C07K16/18 , C07K16/30 , C07K16/303 , C07K2317/73 , C07K2317/76 , C07K2317/77
摘要： The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
-
公开(公告)号：US20100303834A1
公开(公告)日：2010-12-02
申请号：US12827590
申请日：2010-06-30
申请人： BELINDA CAIRNS , Ruihuan Chen , Gretchen Frantz , Kenneth J. Hillan , Hartmut Koeppen , Heidi S. Phillips , Paul Polakis , Susan D. Spencer , Victoria Smith , P. Mickey Williams , Thomas D. Wu , Zemin Zhang , Mark Sliwkowski
发明人： BELINDA CAIRNS , Ruihuan Chen , Gretchen Frantz , Kenneth J. Hillan , Hartmut Koeppen , Heidi S. Phillips , Paul Polakis , Susan D. Spencer , Victoria Smith , P. Mickey Williams , Thomas D. Wu , Zemin Zhang , Mark Sliwkowski
IPC分类号： A61K39/395 , A61P35/00 , C12N5/09 , G01N33/53
CPC分类号： G01N33/57484 , A61K47/60 , A61K47/6803 , A61K47/6809 , A61K47/6817 , A61K47/6839 , A61K47/6851 , A61K47/6859 , A61K51/1006 , A61K51/1018 , A61K2039/505 , C07K16/1072 , C07K16/18 , C07K16/30 , C07K16/303 , C07K2317/73 , C07K2317/76 , C07K2317/77
摘要： The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
摘要翻译： 本发明涉及用于哺乳动物肿瘤诊断和治疗的物质组合物，以及使用这些物质组合物的方法。
-
公开(公告)号：US20120014969A1
公开(公告)日：2012-01-19
申请号：US13181115
申请日：2011-07-12
申请人： Robert Akita , Mark Sliwkowski
发明人： Robert Akita , Mark Sliwkowski
IPC分类号： A61K39/395 , C07K16/46 , C12N5/16 , G01N33/573 , A61P25/00 , C12N1/21 , C12N1/15 , C12N5/10 , A61P35/00 , A61P29/00 , C07K16/40 , C12N1/19
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/32 , C07K2317/55 , C07K2317/76 , G01N33/74 , G01N2333/71
摘要： Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
摘要翻译： 公开了结合ErbB3蛋白并且还具有以下特性中的一种或多种的抗体：在表达ErbB2和ErbB3的细胞中减少asgulin诱导的ErbB2-ErbB3蛋白复合物形成的能力; 增加蛋白对ErbB3蛋白结合亲和力的能力; 以及在表达ErbB2和ErbB3的细胞中减少鸟嘌呤诱导的ErbB2激活的特征。
-
公开(公告)号：US20110293614A1
公开(公告)日：2011-12-01
申请号：US13130789
申请日：2009-11-24
申请人： Klaus Elenius , Maija Hollmen , Mark Sliwkowski
发明人： Klaus Elenius , Maija Hollmen , Mark Sliwkowski
IPC分类号： A61K39/395 , A61P35/00 , G01N33/566 , C07K16/40 , C12N5/09
CPC分类号： C07K16/40 , A61K2039/505 , C07K16/32 , C07K2317/30 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/57492 , G01N2333/71
摘要： Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.
摘要翻译： 公开了用于检测和治疗表达HER4 JM-a同种型的癌症的组合物和方法。
-
8.发明授权公开(公告)号：US07862817B2
公开(公告)日：2011-01-04
申请号：US11044749
申请日：2005-01-27
IPC分类号： A61K39/395 , C07K16/28 , C12P21/08 , C07K14/705
CPC分类号： A61K31/282 , A61K31/337 , A61K31/525 , A61K31/7072 , A61K33/24 , A61K39/395 , A61K45/06 , A61K47/6809 , A61K2039/505 , C07K16/32 , C07K2317/24 , C07K2317/55 , C07K2317/73 , C07K2317/76 , Y10S424/80 , Y10S424/801 , A61K2300/00
摘要： The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
摘要翻译： 本申请描述了人源化抗ErbB2抗体和用抗ErbB2抗体如人源化抗ErbB2抗体治疗癌症的方法。
-
9.发明申请公开(公告)号：US20100136033A1
公开(公告)日：2010-06-03
申请号：US12609737
申请日：2009-10-30
IPC分类号： A61K39/395 , C07K16/00 , A61P35/00
CPC分类号： C07K16/3015 , A01K67/0271 , A01K67/0275 , A01K67/0278 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/052 , A01K2227/105 , A01K2267/0331 , A61K9/0019 , A61K39/39558 , A61K47/6803 , A61K47/6855 , A61K47/6871 , A61K2039/505 , C07K16/2863 , C07K16/32 , C07K2317/24 , C12N15/8509
摘要： The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
摘要翻译： 该应用涉及使用抗ErbB受体抗体 - 美登木素生物碱结合物的治疗方法以及适用于这种方法的制品。 特别地，本发明涉及使用抗ErbB受体抗体 - 美登木素生物碱结合物的ErbB受体指导的癌症治疗。
-
公开(公告)号：US20100135957A1
公开(公告)日：2010-06-03
申请号：US12639822
申请日：2009-12-16
IPC分类号： A61K38/20 , C07K16/00 , C07H21/04 , C12N15/63 , C12N5/00 , C07K16/42 , A61K39/395 , A61K38/21 , A61P35/04 , A61P29/00 , A61P9/00
CPC分类号： C07K14/71 , A61K38/00 , A61K2039/505 , C07K14/4756 , C07K16/32 , C07K19/00 , Y02A50/466 , Y10S435/971
摘要： Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
摘要翻译： 公开了结合天然异源多聚体受体的配体的新型嵌合杂多聚体粘附素及其用途。 杂多聚体粘附素的嵌合分子包含异源多聚体受体单体的细胞外结构域和用于粘附素中嵌合分子的稳定相互作用的多聚化结构域。 具体公开的是包含ErbB2和ErbB3或ErbB2和ErbB4的细胞外结构域的异源多聚体粘附素。 本发明的嵌合ErbB异源多聚体粘附素可用作神经调节蛋白的竞争性拮抗剂或激动剂用于治疗各种癌症等疾病。
-
-
-
-
-
-
-
-
-
搜索结果
54 条记录 (耗时 0.209 秒)
